Related Experiment Video
Updated: Jul 12, 2025
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.3K
A new strategy for cardiac protection.
Esmaa Bouhamida1, Hina W Chaudhry1
1Cardiac Regenerative Medicine Laboratory and the Department of Cardiology, Icahn School of Medicine at Mount Sinai, New York, United States.
Elife
|November 2, 2023
Summary
New research suggests inhibiting the sirtuin 2 (SIRT2) protein may offer a novel therapeutic strategy for treating cardiac hypertrophy and injury. This approach could lead to improved heart health outcomes.
Area of Science:
- Cardiology
- Molecular Biology
- Biochemistry
Background:
- Cardiac hypertrophy and injury are significant contributors to heart failure.
- Sirtuin 2 (SIRT2) is a protein deacetylase implicated in various cellular processes.
- Understanding SIRT2's role in cardiac pathophysiology is crucial for developing targeted therapies.
Discussion:
- Inhibiting SIRT2 may mitigate the cellular damage and structural changes associated with cardiac hypertrophy.
- Modulating SIRT2 activity could represent a novel therapeutic avenue for preventing or reversing cardiac injury.
- Further research is needed to elucidate the precise mechanisms by which SIRT2 influences cardiac health.
Key Insights:
- The study identifies SIRT2 as a potential therapeutic target for cardiac conditions.
- Drug-induced inhibition of SIRT2 shows promise in preclinical models of cardiac hypertrophy and injury.
- Targeting SIRT2 could offer a new strategy to protect the heart from damage.
Outlook:
- Developing specific SIRT2 inhibitors for clinical use in cardiovascular diseases.
- Investigating the long-term effects and safety profile of SIRT2 inhibition in cardiac patients.
- Exploring combination therapies involving SIRT2 modulators and existing cardiovascular treatments.
Related Concept Videos
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
12
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...
12
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
01:29Cardiomyopathy V: Interprofessional Care
14
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
14
01:23Cardiopulmonary Resuscitation III: AED Use
34
Introduction to AEDAn Automated External Defibrillator (AED) is a portable medical device that analyzes the heart's rhythm and, if necessary, delivers an electrical shock to help the heart re-establish an effective rhythm during sudden cardiac arrest (SCA). SCA occurs when the heart suddenly and unexpectedly stops beating, leading to a loss of blood flow to the brain and other vital organs. In such emergencies, time is of the essence, and using an AED, combined with Cardiopulmonary...
34
01:28Acute Coronary Syndrome IV: Interprofessional Care
11
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
11
01:30Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9